Keyword: GlaxoSmithKline (GSK)

News

Glaxosmithkline Says Roche's Herceptin Infringes Patents

22.09.2010 - Drugmaker Glaxosmithkline sued Swiss rival Roche on Tuesday for infringing a patent when it produces its cancer drug Herceptin, according to court documents filed on Monday. Glaxo...

News

Glaxosmithkline Hires Goldman Sachs Banker as new Chief Financial Officer

08.09.2010 - Glaxosmithkline said on Wednesday it had hired Goldman Sachs investment banker Simon Dingemans to succeed Chief Financial Officer Julian Heslop, 59, who will retire next March...

News

Lonza Signs Manufacturing Deal with Glaxosmithkline

08.09.2010 - Swiss drugs industry supplier Lonza will manufacture a number of drug compounds for Britain's Glaxosmithkline, in a sign demand for the Swiss group's products is recovering. Lonza...

News

Glaxosmithkline Head Says No Plan to Bid for Genzyme

07.09.2010 - Glaxosmithkline will not step in as a rival bidder for U.S. biotech Genzyme and take on Sanofi-Aventis, the British drugmaker's head of research and development told a French...

News

EU Regulator Reviews Safety of Glaxosmithkline Swine Flu Jab

30.08.2010 - Europe's drug regulator is reviewing the safety of Glaxosmithkline's Pandemrix swine flu vaccine, which has been given to more than 30 million people in Europe, to examine possible...

News

Novartis/Alcon Deal Cleared by EU Regulators

10.08.2010 - Swiss drugmaker Novartis received approval from EU regulators on Monday to buy a minority stake in Alcon, making it easier for it to take full control of the U.S. eyecare group...

News

Sanofi Investors Oppose Big Hike In Genzyme Bid

04.08.2010 - Sanofi-Aventis investors have urged the drugmaker not to pay more than about $19 billion to land Genzyme, some $10 a share below the price wanted by the U.S. biotech group. Two...

News

Sanofi Shareholders Want Genzyme For About $19 Billion

03.08.2010 - Sanofi-Aventis chief executive Chris Viehbacher should aim to land U.S. biotech group Genzyme for around$19 billion to keep his investors on side, according to institutional...